Therapeutic Antibody Development for Ovarian Cancer

Antibody therapy for ovarian cancer employs monoclonal antibodies to target specific markers on cancer cells, thereby blocking tumor growth signals or tagging the cells for immune system recognition and elimination. Alfa Cytology, supported by a highly skilled research team and state-of-the-art laboratory equipment, is deeply engaged in advancing antibody therapies for ovarian cancer.

Introduction to Therapeutic Antibody

Antibody therapy has emerged as a promising approach in the treatment of ovarian cancer, leveraging the precision of the immune system to target malignant cells. By engaging monoclonal antibodies that specifically recognize and bind to antigens present on the surface of ovarian cancer cells, this therapeutic strategy offers a targeted attack on tumors. Such targeted precision not only enhances the efficacy of the treatment but also minimizes damage to healthy cells, thereby reducing systemic side effects.

Fig.1 Therapeutic targeting of tumour-associated macrophages (TAMs) in ovarian cancer by monoclonal antibodies (mAbs). (OSBORN G, et al., 2022)

Pipeline of Ovarian Cancer Antibody

Below is a pipeline outlining various antibody drugs currently being developed for the treatment of ovarian cancer.

Our Services

Alfa Cytology specializes in the preclinical research of antibodies for ovarian cancer, leveraging advanced experimental techniques to drive the development of innovative antibody therapeutics. Our mission is to provide a robust scientific foundation for these therapeutics and to facilitate future breakthroughs in ovarian cancer treatment.

Monoclonal Antibody

Monoclonal antibodies are used to mimic the immune system's attack on ovarian cancer cells. These antibodies target antigens that are more abundant on ovarian cancer cells than on normal cells. 

Bispecific Antibodies

Bispecific antibodies are engineered to simultaneously bind two different antigens, bridging T-cells and tumor cells to enhance the immune system's attack on ovarian cancer.

Polyclonal Antibodies

Polyclonal antibodies are produced using various B cell lines. These antibodies are a mix of immunoglobulin molecules, each targeting a different part of the same antigen, thus showing more variability than monoclonal antibodies.

Antibody-Drug Conjugates

Polyclonal antibodies are produced using various B cell lines. These antibodies are a mix of immunoglobulin molecules, each targeting a different part of the same antigen, thus showing more variability than monoclonal antibodies.

Workflow of Antibody Development

Antibody development is a sophisticated process that delivers targeted and efficacious therapeutic options for treating ovarian cancer.

Immunize animals (e.g., mice, rabbits) with target proteins or their analogs to induce an immune response.

Immunization Generation

Clone the selected antibodies and insert their genes into an expression system (e.g., E. coli, yeast, or mammalian cells) to produce and purify the antibodies.

Expression and Purification

Target Selection

Identify specific targets based on the mechanisms, pathological features, and relevant biomarkers of ovarian cancer.

Antibody Screening

Extract serum or lymphocytes from immunized animals and screen for antibodies with high affinity for the target.

Functional Evaluation

Assess the antibody's efficacy and safety through in vitro assays (e.g., neutralization, cytotoxicity) and in vivo models (e.g., efficacy and safety assessments in animal models).

Alfa Cytology is dedicated to addressing the challenges in ovarian cancer antibody therapy research through our comprehensive, one-stop service. If you have any questions about our offerings, please do not hesitate to contact us.

! For research use only.